6533b7d1fe1ef96bd125ce7f

RESEARCH PRODUCT

Type 5 phosphodiesterase (PDE5) and the vascular tree: from embryogenesis to aging and disease

Eugenia GuidaSusanna DolciFederica CampoloGiovanni RuvoloEmmanuele A. JanniniCarmela Rita BalistreriClara CrescioliAngela Di BaldassarreCalogera PisanoValeriana Cesarini

subject

0301 basic medicineCell typeAgingVascular smooth muscleMyocytes Smooth MuscleVSMCsEmbryonic DevelopmentECsContext (language use)DiseaseBiologyMuscle Smooth VascularArticle03 medical and health sciences0302 clinical medicinenitric oxidevascular smooth muscle cellsHumansBioresorbable vascular scaffoldCyclic Nucleotide Phosphodiesterases Type 5ECEmbryogenesisPhosphodiesteraseVascular agingCell biologycGMPSettore MED/23ECs; PDE5; VSMCs; cGMP; nitric oxide030104 developmental biologyVascular aging; vascular smooth muscle cells; phosphodiesterasePDE5phosphodiesterase030217 neurology & neurosurgeryFunction (biology)Developmental Biology

description

Highlights • Vascular development depends on the timely differentiation of endothelial and smooth muscle cells, that mutually influence their developmental fate. • Endothelial and vascular smooth muscle cell (VSMC) compartments can mutually influence cell and tissue modifications during vascular aging and in vascular disease. • Keeping in mind that PDE5 is mainly expressed in VSMCs, we surveyed the literature on the role of PDE5 in vascular development, aging and disease. • Although most results have been obtained by PDE5 pharmacological inhibition, no data are available, to date, on vascular development, aging or disease following PDE5 genetic ablation.

yearjournalcountryeditionlanguage
2020-01-01
10.1016/j.mad.2020.111311http://hdl.handle.net/11573/1427426